Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 18

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 18
---
 Day One’s Mission Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life - threatening diseases

Forward Looking Statements 3 This communication contains forward - looking statements. Forward - looking statements are generally identified by the words “expect s”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These forward - looking statem ents include, without limitation, statements related to the anticipated consummation of the acquisition of Mersana and the expected benefit s t herefrom; and other statements that are not historical facts. These forward - looking statements are based on Day One’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from tho se anticipated in such forward - looking statements as a result of these risks and uncertainties, which include, without limitation, risks related t o Day One’s ability to complete the transaction on the proposed terms and schedule, or at all; whether the various conditions to the cons umm ation of the transaction under the merger agreement will be satisfied or waived; whether stockholders of Mersana tender sufficient shares in the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agr eement; the outcome of legal proceedings that may be instituted against Day One, Mersana and/or others relating to the transaction and th e r isk that such legal proceedings may result in significant costs of defense, indemnification and liability; the failure (or delay) to receiv e t he required regulatory approvals relating to the transaction; the possibility that competing offers will be made; disruption from the pro pos ed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the r isk that Day One will not be able to retain the employees of Mersana following the closing of the transaction given the at - will nature of their e mployment; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration ma y be more difficult, time - consuming or costly than expected or that the expected benefits of the transaction will not occur; risks associa ted with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical tr ial s and reporting data; risks related to future opportunities and plans for Mersana and its product candidates, including uncertainty of the ex